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Abstract
Background: Tuberculosis (TB) patients in China still face a number of barriers in seeking diagnosis and treatment.
There is evidence that the economic burden on TB patients and their households discourages treatment compliance.
Methods: A cross-sectional study was conducted in three cities of China. Patients were selected using probability
proportional to size (PPS) cluster sampling of rural townships or urban streets, followed by list sampling from a patient
register. Data were collected using a questionnaire survey, key informant interviews and focus group discussions with
TB patients to gain an understanding of the economic burden of TB and implications of this burden for treatment
compliance.
Results: A total of 797 TB patients were surveyed, of which 60 were interviewed in-depth following the survey. More
than half had catastrophic health expenditure. TB patients with higher household incomes were less likely to report
non-compliance (OR 0.355, 95 % CI 0.140–0.830) and patients who felt that the economic burden relating to TB treatment
was high more likely to report non-compliance (OR 3.650, 95 % CI 1.278–12.346). Those who had high costs for
transportation, lodging and food were also more likely to report non-compliance (OR 4.150, 95 % CI 1.804–21.999). The
findings from the qualitative studies supported those from the survey.
Conclusion: The economic burden associated with seeking diagnosis and treatment remains a barrier for TB patients in
China. Reducing the cost of treatment and giving patients subsidies for transportation, lodging and food is likely to
improve treatment compliance. Improving doctors’ salary system to cut off the revenue-oriented incentive, and
expanding current insurance’s coverage can be helpful to reduce patients’ actual burden or anticipated burden. Future
research on this issue is needed.
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Background
Tuberculosis (TB) remains the most important infectious
disease worldwide. Its etiological agent, Mycobacterium
tuberculosis, infects one-third of the world population
and it accounted for some 1.5 million deaths in 2013
according to WHO estimates [1]. China accounted for
11 % of global TB cases in 2013. It ranked fifth in terms of
the epidemiologic burden of TB, with an incidence rate of
70 per 100,000, a prevalence rate of 94 per 100,000 and an
estimated 3.0 deaths per 100,000 attributed to TB in 2013
[1]. Attaining WHO’s end TB strategy, zero deaths,
disease, and suffering due to TB by 2035, will be a major
challenge [2]. Non-compliance with treatment remains a
central concern [3–6]. The direct observation of treatment
(DOT) approach has proved effective, but, as in many
countries, considerable proportion of non-compliant pa-
tients exist [6–12].
Studies indicated that education level, marital status,
employment, and lack of TB and its treatment related
knowledge were important reasons for non-compliance
[8, 9, 13–15]. A number of studies also assessed related
costs and found that a high economic burden is associ-
ated with poor treatment compliance [16–21].* Correspondence: zhanghui@chinatb.org2National Center for TB Control and Prevention, China CDC, Beijing, PR China
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To reduce the financial burden on and barriers to pa-
tients to facilitate seeking essential healthcare, a “free-TB
service policy” has been implemented [9, 14, 16, 21, 22].
Under this policy, tuberculosis suspects are provided a
free diagnosis and anti-tuberculosis treatment, including
designated first-line TB drugs (6 months for new pa-
tients, 8 months if previously treated), chest X-ray exam-
ination for the first and last months, and sputum smear
test [16, 21, 23–25]. Going with this policy, there are
three service model: dispensary model, specialist model,
integrated model [26]. The dispensary model is the most
prevalent model. A TB dispensary is usually a department
of Centre for Disease Control (CDC), with free treatment
is only provided in this place. General hospitals are just
responsible for referring TB suspects to dispensaries, and
usually are supposed should not treat TB patients, unless
severe or complicated cases. The specialist model is similar
to dispensary model, with severe TB cases should only be
treated in the specialist hospital, but treatment cost in spe-
cialist hospital is not covered by the free treatment policy.
The integrated model is a new development, with the most
popular general hospital in the district, usually called as TB
designated hospital, provides TB treatment. TB dispensary
continues to provide related service but just limited in
training, mass education and case supervision, and should
report and ensure referred TB suspects arrived in the
designated hospital. Expenditure beyond the “free-TB ser-
vice policy” was supposed to be covered by insurance. In
china, health care system is bifurcated in nature between
rural and urban areas [27], and TB patients mainly covered
by government-led complementary insurance programs:
the Urban Employee Basic Medical Insurance (UEBMI),
designed exclusively for urban worker; the Urban Resident
Basic Medical Insurance (URBMI), designed for urban resi-
dents without formal employment; the New Cooperative
Medical Scheme (NCMS), designed for rural population.
Despite the free policy and the cover of insurance, the
medical and non-medical costs incurred by TB patients
and their households are still substantial [16, 28–32].
The phenomenon that requesting repeated investigation,
including blood tests, X-rays and even CT test, and pre-
scribing liver protection and ancillary drugs is not un-
common [10, 16, 21, 25, 33].
Several studies have also found that the anticipation of
a high economic burden and concern with ‘sunk costs’
can affect patient decisions [9, 34–38]. Some patients
may have poor compliance because they expect that the
overall cost of treatment will be high even though their
actual out-of-pocket payments have been relatively lim-
ited. Others who are facing serious financial difficulties
may persevere with treatment because of the considerable
investment in care already undertaken: the sunk cost effect.
The observation of such complex relationships between
economic burden and compliance emphasizes the need for
a combination of qualitative and quantitative approaches.
However, previous studies have generally adopted one ap-
proach. The primary objective of this paper is systematic
research this problem through a mixed method.
Another gap is that previous studies usually focus on
the direct medical cost. Few studies involve with direct
non-medical and indirect costs. For certified low income
and unemployed patients, just transportation cost can
account for a considerable proportion of their annual
household income. How about the relationship between
economic burden incurred by direct non-medical and
indirect costs and treatment compliance? The second
objective of this paper is to fill this gap, and to examine




Since 2009, the Bill & Melinda Gates Foundation, one of
which efforts in China is fighting HIV/AIDS and tuber-
culosis (TB), in collaboration with the National Health
and Family Planning Commission of the People’s Repub-
lic of China (NHPFC), known as the Ministry of Health
before March 2013, and China CDC, has developed and
implemented an innovative program on TB control and
prevention in China. Here we analyze data from a baseline
survey in the three cities where the program was imple-
mented: Zhengjiang City, Jiangsu Province; Yichang City,
Hubei Province; and Hanzhong City, Shaanxi Province.
They are located in the Eastern, Middle and Western Re-
gions of China respectively, with a GDP per capital 73947
RMB, 56265 RMB, and 16935 RMB.
In 2012, the amount of registered TB patients in
Zhengjiang, Hanzhong, and Yichang is 1768, 2336, and
3437, respectively, with an estimated non-compliance
rate, caused by economic burden, 3.0 %, 3.3 % and
5.7 %. The primary service model is the integrated
model. Tuberculosis suspects are provided a free diag-
nosis and anti-tuberculosis treatment, including desig-
nated first-line TB drugs (6 months for new patients,
8 months if previously treated), chest X-ray examin-
ation in the first and last months, and sputum smear
test. The first-line TB drugs are isoniazid, rifampicin,
rifampicin and butyl, pyrazinamide, ethambutol and
streptomycin, and patients are requested to take tests
and bring back their drugs every one or two month.
Study sampling
Due to china’s large population and area, Chinese admin-
istration unit have consisted of several levels, mainly in-
cluding provincial, prefectural, county, township, village.
Prefectural level’s city, for instance Zhengjiang City, can
also be divided into district, and further into street. To
sample adapt to China’s administration unit, Probability-
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Proportional-to-Size Sampling (PPS) was adopted [39, 40].
Using selected key indicators, the required sample size per
city was calculated to be 264 cases. This was rounded up
to 270. As economic situation, to some extent, can stand
for one place’s healthy development condition and peo-
ple’s cognition of health. One county or district was ran-
domly selected in each of three GDP per capita categories
(high, middle and low). Six townships or streets were then
sampled using PPS in each county or district and TB
cases randomly sampled from the notification list. In
total, 797 TB patients were surveyed (263 in Zhenjiang,
270 in Hanzhong and 264 in Yichang) and 60 of these
were selected for in-depth interview.
Data collection
Data collection employed a combination of both quantita-
tive and qualitative methods. A survey questionnaire was
developed which collected data on demographic and socio-
economic information, patient diagnostic and treatment
pathways and history, direct health service expenditures, in-
direct costs (transport and accommodation costs, associ-
ated additional household costs and household income
foregone), borrowing resulting from illness, and compliance
during treatment. We identified non-compliant patients as
those who interrupted or stopped treatment (if not because
of any adverse reactions) or refused treatment. The ques-
tionnaire and survey procedures were tested in a pilot study
carried out in one project site. The survey was conducted
by university students from Huazhong University of Sci-
ence and Technology (Yichang), Xi’an Jiaotong University
(Hanzhong) and Nanjing Medical University (Zhejiang).
These students received appropriate training on interview
skills and the contents of the questionnaire.
Quantitative data were self-reported and self-recalled.
Household income was the aggregate of household in-
come from production, wage incomes of household mem-
bers, transfer income (pensions, remittances, welfare) and
property income (interest, rent) [41–45]. Household in-
come foregone was calculated by days unable to work
since the onset of TB multiplied by the average reported
lost income per day [29, 46]. The collection of direct and
indirect costs followed the approach of Umar et al. [29].
Focus Group Discussions (FGDs) were held with TB pa-
tients. Each county organized one FGD with six to eight
TB patients. A total of nine FGDs were conducted by uni-
versity faculty members. All FGDs were tape recorded
with the permission of participants. The inclusion criter-
ion was simply defined in terms of patients with recent
TB treatment experience who could clearly communicate
their thoughts. As we identified patients from a list of TB
patients compiled at the time that each patient began their
TB regimen, there “recent” means six months or eight
months as the standard course is six months for new
cases and eight months for relapse cases. Each group
was intended to reflect diversity in terms of gender, age-
group and socio-economic status. Patients were selected
with the help of the local CDC officials and informed
about the study and its purpose. 60 of patients were se-
lected, including 18 in Zhenjiang, 19 in Hanzhong and 23
in Yichang. The interviewer used a semi-structured inter-
view guide with questions concerning direct health service
expenditures, travel and subsistence costs, the affordability




 OOP: out-of-pocket payment
 TOOP: total out-of-pocket payment, including direct
medical costs, direct non-medical costs, and indirect
costs, as a percent of household income;
 OOP2: out-of-pocket payment for diagnosis and
treatment as a percent of household income;
 TLF: travel, lodging and food costs as a percent of
household income;
 Irishr: income foregone due to the illness as a
percent of household income;
 DSC: dietary supplement costs as a percent of
household income;
 Ethel: patients’ subjective assessment whether TB
causes a heavy burden to their family;
 Dietary supplement costs are expenditures on
additional food, vitamins. During the period
following diagnosis. Travel and subsistence costs are
expenditures on travel, accommodation and food
while seeking diagnosis and during treatment.
TOOP and OOP2 were defined as “catastrophic” if they
equaled or exceeded 10 % [47, 48]. There is no generally ac-
cepted standard for excessive expenditure on TLF, IncFor
and DSC. In this study, we defined TLF, IncFor and DSC as
“heavy” for cases in which they equaled or exceeded their
median values.
Data management and analysis
Both the quantitative and qualitative data were entered
into relational databases using the double-entry options
of Epidata 3.1 and Nvivo 10, and analyzed with SPSS
20.0 and Nvivo10.
Following descriptive analysis, we used logistic regres-
sion to examine whether treatment compliance was as-
sociated with the extent of the economic burden. Taking
account of the small sample of non-compliance patients,
the bootstrap approach was adopted. Economic burden
indicators are shown in Table 3. Additional variables in-
cluded EcoBur and the household income level. Poten-
tial confounding variables are presented in Table 1. We
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first identified factors that might be expected to vary
substantially between compliant and non-compliant pa-
tients and then included them in analysis using forward
selection [49].
Almost everyone was covered by one of the health insur-
ance schemes, with urban patients usually subscribing to
UEBMI or URBMI and rural patients to NCMS. As indi-
cated in Table 1, at the bivariate level we cannot reject the
hypothesis that insurance type did not vary significantly
between compliant and non-compliant patients. Because of
its policy relevance we retain this variable in regression
model. Finally, Age, UEBMI, URBMI and Education were
therefore included in the regression model. As there were
substantial correlations between all the economic burden
variables, we fitted a separate model for each.
The data is self-reported and it is highly likely that
there will be recall bias. To reduce the impact of data er-
rors and exclude the influence of extreme values we
transformed the continuous variables to generate dichot-
omous or ordinal forms. As this results in a substantial
loss of information we also present findings using the
original variables.
The qualitative data were analyzed using the ‘frame-
work approach’ [50]. The framework was developed
based on a topic guide, with categories emerging from
an initial analysis of the transcripts and applied to the
data to identify themes. All qualitative data were coded,
sorted and classified in terms of this framework. Chart-
ing was used to identify common or divergent percep-
tions and explanations were developed. The Nvivo 10
software package was used to manage the data. All ana-
lysis was conducted in Chinese to avoid translation is-
sues. The final results, including the major themes and
verbatim quotes were then translated into English.
Ethics statement
The Ethics Committee of China CDC gave final approval
for this study (code: 201307). Written informed consent
was obtained from all participants involved in the study.
The ethics committee approved this procedure.
Table 1 Social-economic characteristics of TB patients
Compliant (n = 765) Non-compliant (n = 32) P value*
Sex (female) 193(25.23) 10(31.25) 0.444
Age 56.07(15.02) 60.09(9.72) 0.031**
Residence
Rural 704(92.03) 32(100) 0.225
Urban 59(7.71) 0(0)
Rural- Urban continuum 2(0.26) 0(1)
Education
Primary school and lower 398(52.03) 27(84.38) 0.002
Secondary school or at the same level 265(34.64) 4(12.50)
High school and higher 102(13.33) 0(0)
Employment
Employment 408(53.33) 15(46.88) 0.473
Unemployment 357(46.67) 17(53.12)
Health insurance




Low (lowest 25) 184(24.31) 16(51.61) 0.003
Middle (medium 50) 372(49.14) 10(32.26)
High (top 25) 201(26.55) 5(16.13)
EcoBur
Low 80(10.47) 0(0) <0.001
General 289(37.83) 1(3.12)
High 395(51.70) 31(96.88)
Data are number of patients (%) or mean (SD). Several factors total number is not equal to 764 or 32, due to the existence of missing value. * This value
calculated by chi-square test. **This value calculated by t-test
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Results
Demographic, education, and household income
characteristics of study subjects
Table 1 shows the patient characteristics including their
demographic and economic status. There were almost
three times as many males as females. Most patients
lived in rural areas and participated in the NCMS.
Around 52 % percent had only primary education and
just under 47 % were unemployed. Almost 52 % consid-
ered TB as a heavy economic burden on their family.
Only 32 patients reported poor compliance. Age, level
of education and level of household income were signifi-
cantly different between compliant and non-compliant
patients.
Medical expenditure and economic burden of TB patients
Table 2 shows the medical expenditures of TB patients.
The average total expenditure on diagnosis and treatint
for non-compliant patients is 17597 RMB (median 8400
RMB), and for compliant patients is 10146 RMB (median
5225 RMB). After reimbursed by insurance, the average
OOP payment for diagnosis and treatment is 11164 RMB
(median 4100 RMB) for non-compliant patients, and 7154
RMB (median 4000 RMB) for compliant patients. For non-
compliant patients the average transportation cost and
lodging and food costs is 247 RMB (median 164 RMB) and
881 RMB (median265 RMB), respectively, and for compli-
ant patients the same costs is 251 RMB (median 114 RMB)
and 526 RMB (median120 RMB), respectively. Compared
with non-compliant patients, compliant patients’ average
income reduction due to missed work is higher, with 385
RMB (median 0 RMB) VS 176 RMB (median 0 RMB), and
the similar result for dietary supplement costs with 305
RMB (median 250 RMB) VS 289 RMB (median 200 RMB).
Tested by nonparametric test, the foregoing results don’t
have a significant difference between compliant and non-
compliant TB patients.
Table 3 shows the economic burden on TB patients.
More than half had catastrophic health expenditure
(TOOP ≥ 10 %). The economic burden caused by
OOP2 was also heavy. Nearly half of patients faced a
heavy economic burden due to TLF or DSC. Unexpectedly,
the economic impact of income foregone was very limited
compared with the results from other studies [17, 29]. It is
possible that this concept was not well understood by re-
spondents. The aforementioned burden generally had a
higher proportion of those who were non-compliant, ex-
cept for the burden caused by IncFor, and TOOP and TLF
were significantly different between compliant and non-
compliant patients. Using the unstratified continuous vari-
ables produced similar results (Table 4), except in the case
of DSC, which became significantly different between com-
pliant and non-compliant patients.
The qualitative findings indicate that while basic TB
drugs are provided free of charge, the costs of examina-
tions, tests and adjuvant drugs can be substantial. There
may also be overuse of CT scans and chest X-rays. This
is illustrated in the following responses:
“Within a month, I had two CT scans and a chest X-ray”
“…the cost is high, because of other checks, (such as)
CT scans.”
“…drugs are free, but the examination fees will cost
more than 230 (RMB) per month”
“…some drugs are free, but examination fees and other
adjuvant drug fees are higher (than free drugs would
have cost).”
The qualitative results also show that, for longer courses
of treatment, transport, lodging and food costs can be
considerable:
Table 2 Direct and indirect costs of TB
Compliant Non-compliant P value*
Mean Median [IQR] Mean Median [IQR]
Total costs on diagnosis and treatment 10146 5225[2500–11638] 17597 8400[3000–30000] 0.084
OOP payment for diagnosis and treatment 7154 4000[2000–8000] 11164 4100[2500–11000] 0.356
Transportation cost (including companion members) 251 114[32–280] 247 164[39–365] 0.266
Lodging and food costs (including companion members) 526 120[0–640] 881 265[54–753] 0.248
Income reduction due to missed work days/hours 385 0[0] 176 0[0] 0.320
(including companion members)
Dietary supplement costs 305 250[120–400] 289 200[200–500] 0.899
Sold 4083 2750[1500–8000] 6000 6000[6000–6000] -
Borrow 10586 5000[3000–15000] 12515 4000[1500–20000] -
Data are mean and median (IQR)
*This value calculated by nonparametric test
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“Treatment time is long, (needing) eight or nine
months… travel (cost) alone is high.”
“(Transportation, lodging and food costs) will probably
be more than 1000 (RMB). Almost 10000 (RMB) a
year.”
“…travel cost? Thousands of RMBs. (About) three or
four thousands.”
“…like me, come here every month. (Every time I
needed) at least 300 (RMB). Round-trip travel expenses
will be at least 100 (RMB), (and this does) not include
accommodation. … Nobody gives you reimbursement.”
The influence of a high economic burden on patient
compliance
Logistic regression suggests that TB patient treatment com-
pliance was related to TOOP, household income, EcoBur
and TLF (Table 5). After adjustment for confounding fac-
tors the main findings were that: TB patients with middle
level household incomes were less likely to occur non-
compliance than those with low household income (OR
0.355, 95 % CI 0.140-0.830); those who felt EcoBur was
general or high were more likely to occur non-compliance
than those who felt it was low (OR 2.274, 95 % CI 1.081-
10.928; OR 3.650, 95 % CI 1.278-12.346, respectively); and
TB patients with high TLF were more likely to occur non-
compliance than those with low (OR 4.150, 95 % CI 1.804-
21.999). There was no significant difference in treatment
compliance resulting from the economic burdens of OOP2,
IncFor or DSC.
Similar results were obtained with the untransformed
continuous variables allowing for the effects of age, UEBMI,
URBMI, and education, as shown in Table 4. Again, the ef-
fect of expenditure on DSC became significant.
Qualitative findings suggest that, for some patients, even
the burden of transport costs can influence their treat-
ment compliance, especially for families with more than
one TB patient.
“… (The) travel cost is high, (and) influenced me (in
terms of compliance)”
“There is a family, all (have) tuberculosis. If they were
examined, in fact, they could be cured, but (because
they) don’t (have) money they are unwilling to travel
(for treatment).”
Discussion
In this study, we found that age, education level, household
income and patients’ subjective assessment whether TB
causes a heavy burden to their family are significant differ-
ent between group compliance and non-compliance. In
consistence with previous studies, we also got the similar
result that patients who are elderly, low education
level are more likely to non-compliance to TB treat-
ment [8, 9, 14, 15]. The elderly and low education
level patients are more likely to have a limited ability
to get and understand related TB knowledge. This cue
that except the chemotherapy, a humanist interven-
tion or assistance may be needed.
Compared with direct medical costs, the non-medical
costs, dietary supplement costs and indirect costs were
not high. This finding is not consistent with other studies,
Table 3 Direct and indirect costs as % of household income of
TB patients
Compliant (n = 765) Non-compliant (n = 32) P value*
TOOP (n = 737)
Heavy (=1) 479(67.56) 24(85.71) 0.043
OOP2 (n = 758)
Heavy (=1) 427(58.41) 20(74.07) 0.104
TLF (n = 775)
Heavy (=1) 368(49.20) 22(81.48) 0.001
IncFor (n = 789)
Heavy (=1) 78(10.30) 2(6.25) 0.763
DSC (n = 521)
Heavy (=1) 274(53.52) 7(77.28) 0.188
Data are number of patients (%). TOOP and OOP2 were defined as “catastrophic”
or “heavy” if they equaled or exceeded 10 %, and TLF, IncFor and CDS were
defined as “heavy” if it equaled to or exceeded its median.* This value calculated
by chi-square test
Table 4 Direct and indirect costs as % of household income of TB patients*
Compliant Non-compliant p-value** p-value***
Mean Median [IQR] Mean Median [IQR]
TOOP 71.74 20[7.67–50] 248.89 36.25[15.83–158.33] 0.001 0.006
OOP2 47.33 13.12[5.17–37.35] 164.43 20.23[7.91–93.66] <0.001 0.058
TLF 8.38 1.63[0.32–6.52] 49.17 6.29[2–22.5] 0.001 0.003
IncFor 1.96 0[0–0] 0.44 0[0–0] 0.874 0.697
DSC 2.46 1[0.5–2.26] 4.67 4.29[2.04–6.94] 0.009 0.019
Household income 31336.52 22000[8000–41000] 19681.94 7860[2000–24500] 0.056 <0.001
*The variable is same with variable shown in Tables 3 and 5, but have not been transformed into categorical variable
**This value calculated by ANOVA based on log transformation
***This value calculated by ANCOVA based on log transformation, the covariate was Age, UEBMI, URBMI, and Education
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which often indicate that the main burden arises from
transport, diet supplements and loss of income [17, 46].
Explanation is that most of the patients were located in
rural areas with incomes mainly coming from farming or
self-employment (Table 2). The time required for diagno-
sis and treatment have little impact on the time available
for work and the food for diet supplementation usually be
home grown.
Though the free-TB service policy, patients have to pay a
high expenditure on diagnosis and treatment. Even though
covered by insurance, this expenditure doesn’t reduce too
much. In the integrated model, TB patients can only be di-
agnosed and treated under the free treatment policy in the
designated hospital. The free treatment policy just cov-
ered first-line anti-TB drugs, TB sputum smears and
cultures, and X-ray examinations for the first and last
months [16, 21, 23, 24, 51], and these items’ profit is
low. Driven by the revenue, doctors may over-prescript
additional drugs and test [16, 33]. As the qualitative re-
sults showed, overuse of liver protection drugs and CT
test is not uncommon. And also previous studies revealed
that providers have the motivation to use second-line anti-
TB drugs [16, 21, 26]. All these overused items neither cov-
ered by the free policy, nor by the insurance, resulting in
high patient OOP medical expenditure. A systematic review
based on 85 research articles found no reliable evidence to
support prescription of drugs protects the liver [52]. studies
also reported that NCMS did not reduce patient out-of-
pocket costs per episode [31, 53, 54]. All of these indicated
that improving providers’ salary system, expanding insur-
ance’s coverage is needed.
This study revealed a very high economic burden for TB
patients in China, in line with prior studies [16, 28, 29, 55].
Almost 68 % of TB patients reported catastrophic health
expenditure (Table 3), much higher than the average for
China [43, 44]. Patients with low household incomes or
who felt that the economic burden was high were more
likely to occur non-compliance (Table 5). These findings
lend support to the argument that there is an association
between TB and poverty and suggests that TB patients still
face economic barriers in seeking diagnosis and treatment
[20, 28, 30].
Contrary to expectations, the quantitative analysis sug-
gests that a high economic burden did not in itself result
in poor compliance (Table 5). This finding has two pos-
sible explanations. First, a sunk cost effect probably ex-
ists in relation to seeking diagnosis and treatment. If a
patient has spent a lot of money at early stage, he or she
may continue to seek treatment, to avoid that expend-
iture becoming a sunk cost, even borrowing money or
selling property to continue treatment. Second, in the
process of calculating the economic burden, we only in-
clude the actual costs, not the anticipated costs. Patients
with low household incomes may interrupt their treat-
ment because they expect that further treatment will
become unaffordable [9]. Such patients would certainly
feel that the economic burden of treatment was very
high. And these reasons can also explain why we can’t
get a significant result from the test of direct and indir-
ect costs between compliant patients and non-compliant
patients.
Even the costs related to transport, accommodation and
food could lead to catastrophic expenditure (Table 3). And
the results from both from quantitative and qualitative
studies demonstrate that the burden from costs on trans-
port, lodging and food had a substantial effect on treatment
Table 5 Logistic regression of economic burden’s effect on TB patients’ compliance with OR and adjusted OR
Pre-adjusted Adjusteda
p-value OR (95 % CI) p-value Adjusted OR (95 % CI)
TOOP (=1) 0.032 2.811(1.207–13.971) 0.07 2.406(0.939–12.244)
OOP2 (=1) 0.096 2.034(0.926–7.199) 0.18 1.822(0.766–6.013)
TLF (=1) 0.003 4.545(1.850–21.999) 0.001 4.150(1.804–21.999)
IncFor (=1) 0.396 0.580(0.000–1.697) 0.653 0.829(0.000–2.754)
DSC (=1) 0.094 3.040(0.689–20.589) 0.155 2.622(0.500–25.815)
Household income
Low (lowest 25 %)
Middle (medium 50 %) 0.001 0.309(0.121–0.657) 0.011 0.355(0.140–0.830)
High (top 25 %) 0.008 0.286(0.061–0.709) 0.155 0.419(0.066–1.435)
EcoBur
Low
General 0.047 2.300(1.091–8.987) 0.037 2.274(1.081–10.928)
High 0.002 3.333(1.113–10.989) 0.001 3.650(1.278–12.346)
aAdjusted for the variable Age, UEBMI, URBMI, and Education
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compliance, in line with Tadesse’s study [3].This also lend
supports to the hypothesis above. In China, under the free
policy, providers are supposed to educate TB patients re-
lated knowledge before chemotherapy. Previous studies in-
dicated several points: lack of knowledge about anti-TB
treatment was associated with higher non-compliance rates
[8, 13]; some patients still confused about treatment regi-
men after health education [8]; adverse reactions contrib-
ute to non-compliance [15, 21]. For patients with low
household income, if adverse reactions occurred or symp-
toms relieved and can’t convenient keep in touch with
doctors, travelling long distances to a health care facility at
considerable expense will challenge their willingness to
continue treatment [3, 16]. Another situation is that as pa-
tients have to bring back their medicine monthly, the high
cost of transport, lodging and food really impede them
from doing so.
What can we do to improve TB patients’ compliance?
We suggest we can through two aspects to influence pa-
tients’ behavior: knowledge and economic burden. As
we discussed before, for patients, transport, accommo-
dation and food costs can be a barrier to keep in touch
with doctors. So one of the useful ways is to develop
mobile phone based intervention, as several studies
already emphasize this intervention’s potential effect-
iveness [56–58]. Another way is to expand the current
package to cover patients’ transport, accommodation
and food costs or offer related economic assistance. Previ-
ous studies indicated that lack of knowledge about anti-
TB treatment was associated with higher non-compliance
rates [8, 13], and some patients still confused about treat-
ment regimen after health education [8]; we found that
patients who are elderly, low education level are more
likely to non-compliance to TB treatment. This implied
that a humanist intervention tailored by these factors may
be helpful.
For economic burden, no matter actually happened
burden or anticipated burden, an experience-based opin-
ion is that due to the free-TB service policy, the eco-
nomic burden caused by OOP2 just happened when
patients already played a visit to doctor, otherwise they
wouldn’t know or anticipate whether the burden is high.
According to the above discussion, improving doctors’
salary system to cut off the revenue-oriented incentive,
and expanding current insurance’s coverage is useful.
Chinese insurance is a multilevel system. In our study,
the actually happened economic burden is high. To en-
hance the cooperation between different level’s insur-
ance, for instance between basic insurance and critical
illness insurance or assistance, is necessary.
Limitations
The proportion of non-adherence in our study is not
high compared with that were reported in previous
studies [8–11], and much of the difference may be due
to differences in study design and definition of non-
adherence to anti-TB treatment. As we want to evaluate
economic burden’s effect, we identified non-compliant pa-
tients as those who interrupted or stopped treatment (if
not because of any adverse reactions) or refused treat-
ment. We identified patients from a list of TB patients
compiled at the time that each patient began their TB
regimen. Some of patients may not be on this list, espe-
cially those located in remote rural areas, who are more
likely to be non-compliant because of the long distance to
the health care facility. In addition, suspected TB patients
were not included in our study. So, as a matter of fact, the
situation is more serious, and the effect of economic bur-
den on compliance may therefore be underestimated.
In our study, we included three sample cities, located
in the Eastern, Middle and Western regions of China,
respectively. Background of the studied setting is differ-
ent more or less, and the more appropriate analysis is
disaggregate patients by the three regions. Due to the
limitation of sample size of non-compliance patients,
this method will come with high risk of deviation. Fur-
ther study with more sample size is needed to explore
inter-regional difference.
To avoid the influence of inaccurate data and extreme
values and to simplify interpretation of the regression re-
sults, we transformed several continuous variable to or-
dered category form, though this had little impact on the
results. However, recall bias will still almost certainly have
influenced the findings. The economic impact of income
foregone was very limited compared with the results from
other studies [17, 29]. It is possible that this concept was
not well understood by respondents.
Conclusion
Our results lend weight to the argument that there is
a link between TB and poverty and that TB patients
continue to face economic barriers in seeking diag-
nosis and treatment. TB patients with low household
incomes or who feel that the economic burden of
treatment is high are more likely to have poor com-
pliance. As indicated above, the number of TB pa-
tients in China is very large. The provision of free
anti-TB drugs has been a valuable step forward but
to improve the coverage and effectiveness of control
programs for TB. We suggest that the useful way is to
develop mobile phone based intervention or offer patients
transport, accommodation and food economic assistance
to break down the barrier of keeping in touch with doc-
tors. Another way is to improve doctors’ salary system to
cut off the revenue-oriented incentive, expand current in-
surance’s coverage, and enhance cooperation between dif-
ferent level’s insurance.
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